AsiaOligonucleotide, Peptide
Shanghai Waigaoqiao, China
Discovery Synthesis for Oligonucleotide, Peptide & Conjugate Pre-formulation & Formulation Development for Oligonucleotides, Peptides & Conjugates
Site detail
Asia
Changzhou, China
API Process Development and Manufacturing for Oligonucleotides, Peptides & Conjugates
Please contact us for the full virtual tour.
API Process Development and Manufacturing for Oligonucleotides, Peptides & Conjugates
- 589 North Yulong Road XinBei District, Changzhou, 213127, China
The site offers API process development and manufacturing for oligonucleotides, peptides & conjugates from preclinical to commercial manufacturing.
The 74-acre campus offers a unique one-site solution for oligonucleotides, peptides, and related synthetic conjugates with approximately 30 oligonucleotide manufacturing lines at various scales and over 20 peptide production lines. When combining the peptide capacity in our Taixing site, the total reactor volume of solid-phase peptide synthesizers at WuXi TIDES has reached over 41,000 L.
We have recently opened our new R&D Center in Changzhou, significantly expanding our capabilities in developing advanced therapies covering small molecules, oligonucleotides, and peptides as well as complex synthetic conjugates. Strategically located just 15 minutes from our existing Changzhou API manufacturing site, the R&D Center is designed with six R&D buildings. Upon full operation, the Center will accommodate approximately 3,000+ scientists with 170+ specialized laboratories. The first operational building, dedicated to API development for oligonucleotides, peptides, and complex synthetic conjugates, spans over 160,000 square feet. The modular lab integrates essential workflows with latest digitalization and automation controls to achieve faster data turnaround and higher efficiency.
Our Changzhou site has successfully passed numerous inspections by the US FDA, China NMPA, Japan PMDA, South Korea MFDS, and Brazil ANVISA. More specifically, the site recently passed a PAI for a new peptide drug from Japan PMDA.
Site Virtual Tour
Site Related News
WuXi AppTec’s Changzhou and Taixing API Sites Successfully Pass FDA Inspections
Shanghai, China – April 1, 2025 — WuXi AppTec, a global company that provides a broad portfolio of R&D and m...
WuXi AppTec Opens New R&D Center in Changzhou, China
First operational building dedicated to API development for oligonucleotides, peptides...
WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site
Expansion Boosts Solid-Phase Peptide Synthesis Total Reactor Volume to 32,000 Liters in Response to Surging Demand Shangh...
Three Sites from WuXi STA Receive Top EcoVadis Scores for Business Sustainability Rating
WuXi STA, a subsidiary of WuXi AppTec, received the latest scores from EcoVadis rating, a trusted provider of business sustainability ratings, for act...
WuXi AppTec’s Changzhou and Taixing API Sites Successfully Pass FDA Inspections
Shanghai, China – April 1, 2025 — WuXi AppTec, a global company that provides a broad portfolio of R&D and m...
WuXi AppTec Opens New R&D Center in Changzhou, China
First operational building dedicated to API development for oligonucleotides, peptides...
WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site
Expansion Boosts Solid-Phase Peptide Synthesis Total Reactor Volume to 32,000 Liters in Response to Surging Demand Shangh...
Three Sites from WuXi STA Receive Top EcoVadis Scores for Business Sustainability Rating
WuXi STA, a subsidiary of WuXi AppTec, received the latest scores from EcoVadis rating, a trusted provider of business sustainability ratings, for act...
Nearby in the network
Other sites
How can we help?
Our TIDES drug experts stand ready.
Tell us where your molecule is today — discovery, CMC, or commercial supply — and we will map the fastest credible route to patients.
Small molecule projects? WuXi STA